- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Following the Patient's Lead
The old adage “the doctor knows best” affirms patients’ trust in a physician’s impartial and expert opinion in matters of health, but can physicians continue to be solo managers of patient care? At Newton Medical Center in Newton, NJ, Renee C. Comizio, M.D., M.S., board-certified plastic and reconstructive surgeon, is providing an avenue for breast cancer patients to take an active role in defining their own treatments through shared decision-making.
The shared decision-making program is founded in the belief that each patient has the right to choose the most appropriate medical treatment for his or her life and medical concern. An informed medical decision ensures safety and personalized care while reducing the chance of treatment being tailored to the physician’s preference rather than the patient’s needs and desires.
Read more at: http://www.mdnews.com/news/2011_12/05782_novdec2011_following-the-patient
Source: MDNews.com
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Powles Highlights “Transformative” Benefit of EV Plus Pembro While Sharing Long-Term Data for EV-302
February 15th 2025The lead investigator for EV-302 said not long ago, survival of 12 to 14 months in this type of bladder cancer was considered an achievement; in this study, median overall survival was 34 months after treatment with enfortumab vedotin (EV) and pembrolizumab (pembro).
Read More
Analysis Looks at Benefits, Toxicity of ADC Combinations in Advanced Bladder Cancer
February 15th 2025City of Hope's Salvador Jaime-Casas, MD, discusses a systematic review of recent trials examining objective response rate and adverse events of antibody-drug conjugate (ADC) combinations in advanced urothelial cancer.
Read More
